For some of the candidates, no commercial antibodies have been developed, resulting in limited information about their distribution and concentration in the brain tissues or CSF (for example, VSTM2B protein previously linked to pathogenesis of ataxia telangiectasia [30]). Here, VSTM2B is linked to ataxia telangiectasia.